Table 3

Comparison of age, duration of disease, final dose, frequency of administration of canakinumab and number of adjustments (dose and/or frequency) performed during 12 months in patients with MWS and CINCA

Muckle-Wells

(6 patients)1

CINCA

(7 patients)

P-value2


Age, years, median (range)

13.6 (10.7, 23.7)

15 (8.7, 38.0)

0.56*

Disease duration, median, years (range)

13,6 (3.0, 23.2)

15 (8.7, 38.0)

0.61*

Dose, mg/kg, median (range)

2.15 (2.0, 3.7)

3.7 (2.0, 5.9)

0.16*

Frequency, weeks, median (range)

8 (6, 10)

6 (4, 8)

0.03

Adjustments/year, number

2

9

0.05


1Includes two patients with a Muckle-Wells syndrome (MWS)/chronic infantile neurological cutaneous and articular syndrome (CINCA) phenotype; 2Mann-Whitney U-test, *not significant.

Caorsi et al. Arthritis Research & Therapy 2013 15:R33   doi:10.1186/ar4184

Open Data